The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Single-dose infusion ketamine and non-ketamine N -methyl- d -aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
Open accessAbstract
Background: Ketamine and non-ketamine N -methyl- d -aspartate receptor antagonists (NMDAR antagonists) recently demonstrated antidepressant efficacy for the treatment of refractory depression, but effect sizes, trajectories and possible class effects are unclear. Method: We searched PubMed/PsycINFO/Web of Science/clinicaltrials.gov until 25 August 2015. Parallel-group or cross-over randomized controlled trials (RCTs) comparing single intravenous infusion of ketamine or a non-ketamine NMDAR antagonist v. placebo/pseudo-placebo in patients with major depressive disorder (MDD) and/or bipolar depression (BD) were included in the analyses. Hedges’ g and risk ratios and their 95% confidence intervals (CIs) were calculated using a random-effects model. The primary outcome was depressive symptom change. Secondary outcomes included response, remission, all-cause discontinuation and adverse effects. Results: A total of 14 RCTs (nine ketamine studies: n = 234; five non-ketamine NMDAR antagonist studies: n = 354; MDD = 554, BD = 34), lasting 10.0 ± 8.8 days, were meta-analysed. Ketamine reduced depression significantly more than placebo/pseudo-placebo beginning at 40 min, peaking at day 1 (Hedges' g = −1.00, 95% CI −1.28 to −0.73, p < 0.001), and loosing superiority by days 10–12. Non-ketamine NMDAR antagonists were superior to placebo only on days 5–8 (Hedges' g = −0.37, 95% CI −0.66 to −0.09, p = 0.01). Compared with placebo/pseudo-placebo, ketamine led to significantly greater response (40 min to day 7) and remission (80 min to days 3–5). Non-ketamine NMDAR antagonists achieved greater response at day 2 and days 3–5. All-cause discontinuation was similar between ketamine ( p = 0.34) or non-ketamine NMDAR antagonists ( p = 0.94) and placebo. Although some adverse effects were more common with ketamine/NMDAR antagonists than placebo, these were transient and clinically insignificant. Conclusions: A single infusion of ketamine, but less so of non-ketamine NMDAR antagonists, has ultra-rapid efficacy for MDD and BD, lasting for up to 1 week. Development of easy-to-administer, repeatedly given NMDAR antagonists without risk of brain toxicity is of critical importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peak antidepressant effect of ketamine is seen 24 hours post administration, with sustained effects lasting 1-2 weeks 43 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The antidepressant effects of an acute dose of ketamine are typically thought to occur within hours, peak around 24 h then gradually decline over a period of 10-12 days [10].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine's antidepressant effects peak 1 day following infusion and typically dissipate 1-2 weeks after a single infusion (Kishimoto et al, 2016).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Kishimoto et al, 2016
In the citing paper
“Multiple meta-analyses55–59 have now concluded that intravenous ketamine is effective as a rapid-acting antidepressant for major depressive episodes in both unipolar and bipolar depression”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
In the citing paper
“While several of these studies have supported claims that ketamine’s antidepressant effect lasts up to 7 days,55,56 other authors have suggested this to be true only for unipolar depression.”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
In the citing paper
“Furthermore, a meta-analysis of single-infusion non-ketamine NMDA receptor antagonists, including traxoprodil, lanicemine and rapastinel (GLYX-13), showed smaller effect sizes in depressive symptom change in comparison with ketamine and non-superiority in remission compared with placebo for unipolar and bipolar depression.55”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
In the citing paper
“A major meta-analysis indicated no difference between ketamine and placebo groups on patient reports of ‘tired/fatigued’ and ‘vivid dreams’.55”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
RetractedThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Research works printed but not linked: 1
- Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0
Cited by
Sorted by citations
Items 201–300 of 359
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 15
Liu, W., Zhou, Y., Wang, C., Zheng, W., Zhan, Y., Lan, X., Zhang, B., Li, H., Chen, L., Li, M., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.048 · Cited by 15
Wan, X., Li, M., Li, X., Dai, H., & Peng, M. (2024) · Medicine · doi:10.1097/md.0000000000040295 · Cited by 15
Kadriu, B., Deng, Z., Kraus, C., Henter, I. D., Lisanby, S. H., & Zarate, C. A. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19ac13138 · Cited by 15
Self-citation“Novel Psychopharmacology for Depressive Disorders”
Fornaro, M., Berardis, D. D., Anastasia, A., & Fusco, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_22 · Cited by 15
Schiweck, C., Lutin, E., Raedt, W. D., Cools, O., Coppens, V., Morrens, M., Hoof, C. A. V., Vrieze, E., & Claes, S. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.696170 · Cited by 16
Driver, C., Jackson, T., Lagopoulos, J., & Hermens, D. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110609 · Cited by 17
Zhang, Q., Xue, Y., Wei, K., Wang, H., Ma, Y., Wei, Y., Fan, Y., Gao, L., Yao, H. P., Wu, F., et al. (2023) · Advanced Science · doi:10.1002/advs.202303503 · Cited by 14
Rodríguez-Mayoral, O., Pérez‐Esparza, R., Domínguez-Ocadio, G., & Allende‐Pérez, S. (2019) · Palliative & Supportive Care · doi:10.1017/s1478951519000580 · Cited by 15
-, M. A. S., Reyazuddin, M., Gaur, R. K., & Andrade, C. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104413 · Cited by 13
Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review
Balachandran, A., Tassone, V. K., Adamsahib, F., Passa, A.-M. D., Kuburi, S., Demchenko, I., Ladha, K. S., & Bhat, V. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.1022767 · Cited by 13
Rhee, T. G., Shim, S. R., Popp, J. H., Trikalinos, T. A., Rosenheck, R. A., Kellner, C. H., Seiner, S. J., Espinoza, R. T., Forester, B. P., & McIntyre, R. S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02366-8 · Cited by 12
Darwish, M. Y., Helal, A. A., Othman, Y. A., Mabrouk, M. A., Alrawi, A., Ashraf, T. A.-E., Abdelsattar, N. K., Sayed, F. M., & Abd‐ElGawad, M. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07186-y · Cited by 12
A continuum hypothesis of psychotomimetic rapid antidepressants
Haarsma, J., Harmer, C. J., & Tamm, S. (2021) · Brain and Neuroscience Advances · doi:10.1177/23982128211007772 · Cited by 13
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
Ketamine sedation in the intensive care unit: a survey of Canadian intensivists
Sharif, S., Munshi, L., Burry, L. D., Mehta, S., Gray, S. H., Chaudhuri, D., Duffett, M., Siemieniuk, R. A. C., & Rochwerg, B. N. (2023) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-023-02608-x · Cited by 12
Magnesium and ketamine in the treatment of depression.
Górska, N., Słupski, J., Szałach, Ł. P., Włodarczyk, A., Szarmach, J., Jakuszkowiak‐Wojten, K., Gałuszko‐Węgielnik, M., Wilkowska, A., Wiglusz, M. S., & Cubała, W. J. (2019) · PubMed · Cited by 12
Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
Zhang, X., Qing, M.-J., Rao, Y.-H., & Guo, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09726-5 · Cited by 12
Yu, W., Wu, Z., Li, X., Ding, M., Xu, Y., & Zhao, P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03474-w · Cited by 11
Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023
Zhao, L.-Y., Zhang, G.-F., Lou, X.-J., Hashimoto, K., & Yang, J. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01809-9 · Cited by 11
Zhang, K., Jia, G., Xia, L., Du, J., Gai, G., Wang, Z., Cao, L., Zhang, F., Tao, R., Liu, H., et al. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01103-4 · Cited by 11
Li, X., Shi, Z.-M., Wang, P., & Hu, H. (2020) · General Psychiatry · doi:10.1136/gpsych-2019-100117 · Cited by 11
Rodek, P., Kowalczyk, M., Kowalski, J., Owczarek, A. J., Choręza, P. S., & Kucia, K. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195914 · Cited by 10
Zheng, W., Zhou, Y., Wang, C., Lan, X., Zhang, B., Zhou, S., Yan, S., Yang, M., Nie, S., & Ning, Y. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211014320 · Cited by 10
Zheng, W., Gu, L.-M., Zhou, Y., Wang, C., Lan, X., Zhang, B., Li, Z., & Ning, Y. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220927085706 · Cited by 10
Bottemanne, H., Claret, A., & Fossati, P. (2020) · L Encéphale · doi:10.1016/j.encep.2020.08.006 · Cited by 12
Meiering, M. S., Weigner, D., Gärtner, M., Schäfer, T., & Grimm, S. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.10.062 · Cited by 11
Zheng, W., Zhou, Y., Wang, C., Lan, X., & Ning, Y. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.120 · Cited by 10
Ketamine as anaesthesia for ECT: is there room to improve a gold standard treatment?
Andrade, C. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2017.15 · Cited by 10
Psychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 11
The effect of low-dose esketamine on maternal depression after cesarean delivery
Shang, Y., Li, S., Zheng, Q., Mi, T., Lv, Y.-Z., Han, L., & Wang, B.-R. (2025) · Journal of Psychosomatic Obstetrics and Gynaecology · doi:10.1080/0167482x.2025.2527659 · Cited by 9
Kramer, H. M., Hibicke, M., Middleton, J. W., Jaster, A. M., Kristensen, J. L., & Nichols, C. D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02272-3 · Cited by 9
Zhou, Y., Peng, Y., Fang, J., Sun, W., Zhang, G., Zhen, L., Wang, G., & Han, R. (2018) · Trials · doi:10.1186/s13063-018-2831-0 · Cited by 9
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Trueman, H., de Boer, M. K., Schoevers, R. A., & McShane, R. H. (2018) · BJPsych Open · doi:10.1192/bjo.2018.51 · Cited by 9
Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression
Pérez‐Esparza, R., Kobayashi-Romero, L. F., Mendoza, A. M. G., Lamas-Aguilar, R., & Fonseca-Perezamador, A. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13063 · Cited by 9
Wang, C., Lan, X., Liu, W., Zhan, Y., Zheng, W., Chen, X., Liu, G., Mai, S., Lu, H., McIntyre, R. S., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03027-2 · Cited by 8
Jenkins, A. R., Radl, D. B., Kornecook, T. J., Pizzagalli, D. A., Bergman, J., Buhl, D. L., O’Donnell, P., & Kangas, B. D. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103572 · Cited by 8
Li, Y., Zhao, K., Cao, P., Wang, Q., Li, K., Zhang, J., & Zhou, J. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07809-4 · Cited by 8
Scheil, K., Sánchez-Lafuente, C. L., Reive, B. S., Halvorson, C. S., Floyd, J., Reid, H. M. O., Johnston, J. N., Kalynchuk, L. E., & Caruncho, H. J. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110998 · Cited by 9
Chen, M., Wu, H.-J., Li, C., Lin, W., Tsai, S., Hong, C., Tu, P., Bai, Y., Mao, W., & Su, T. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.11.006 · Cited by 8
Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients
Lan, X., Zhou, Y., Wang, C., Li, W., Zhang, F., Liu, H., Fu, L., Wu, K., McIntyre, R. S., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.793677 · Cited by 8
Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Kutscher, M., Vischjager, M., van der Meij, A., Kamphuis, J., & Schoevers, R. A. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14267 · Cited by 8
Donig, A., & Hautzinger, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.1888205 · Cited by 8
Shim, S. R., Jeong, H. S., Bommersbach, T. J., Nierenberg, A. A., Zarate, C. A., Kaster, T. S., Correll, C. U., McIntyre, R. S., Krystal, J. H., & Rhee, T. G. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0612 · Cited by 8
Self-citationCartágenes, S. D. C., da Silveira, C. C. S. D. M., Pinheiro, B. G., Fernandes, L. M. P., Farias, S. V., Kobayashi, N. H. C., de Souza, P. H. F. S., do Prado, A. F., Ferreira, M. K. M., Lima, R. R., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111373 · Cited by 7
Depression, an unmet health need in Africa: Understanding the promise of ketamine
Millen, A. M. E., Daniels, W. M. U., & Baijnath, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28610 · Cited by 7
Juneja, K., Afroze, S., Goti, Z., Sahu, S., Asawa, S., Bhuchakra, H. P., Natarajan, B., & Pandey, S. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00077-2 · Cited by 7
Time until relapse after augmentation with single‐dose ketamine in treatment‐resistant depression
Pérez‐Esparza, R., Corona, T., Ruiz‐Garcia, R., Oñate‐Cadena, N., de la Fuente‐Sandoval, C., & Ramírez‐Bermúdez, J. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12675 · Cited by 7
Ketamina, un nuevo agente terapéutico para la depresión
Pérez‐Esparza, R., Kobayashi-Romero, L. F., Mendoza, A. M. G., Lamas-Aguilar, R., Sosa, M. V., Encarnación-Martínez, M., González-Manríquez, L. A., Eternod-Rodríguez, S. A., Maltos-Gómez, F., Vargas-Valencia, K. M., et al. (2020) · Revista de la Facultad de Medicina UNAM · doi:10.22201/fm.24484865e.2020.63.1.02 · Cited by 9
Gallagher, B., Foley, M., Slattery, C. M., Gusciute, G., Shanahan, E., & McLoughlin, D. M. (2020) · HRB Open Research · doi:10.12688/hrbopenres.13182.1 · Cited by 7
Spider Neurotoxins as Modulators of NMDA Receptor Signaling
Pałasz, A., & Krzystanek, M. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08692-w · Cited by 7
Definition and Epidemiology of Treatment Resistance in Psychiatry
Smith-Apeldoorn, S. Y., Veraart, J. K. E., & Schoevers, R. A. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_1 · Cited by 8
Online news media reporting of ketamine as a treatment for depression from 2000 to 2017
Gallagher, B., Neiman, A., Slattery, M.-C., & McLoughlin, D. M. (2021) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2021.47 · Cited by 7
Zheng, W., Gu, L.-M., Zhou, Y., Wang, C., Lan, X., Zhang, B., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.855995 · Cited by 7
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha, M., Marcinowicz, P., Komarnicki, J., Tobiaszewska, M., Dębowska, W., Dębowska, M. D., & Szulc, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1398859 · Cited by 8
Meiering, M. S., Weigner, D., Gärtner, M., Carstens, L., Keicher, C., Hertrampf, R., Beckmann, C. F., Mennes, M., Wunder, A., Weigand, A., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03120-6 · Cited by 7
Preclinical behavioral and pharmacological treatments for enhancing fear extinction in adolescence
Wall, E. K., Virakorn, E. A., Baker, K., Cohen, E. M., & Richardson, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106090 · Cited by 6
Zhan, Z., Wang, X., Chen, Q., Xiao, Z., & Zhang, B. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043457 · Cited by 6
Zheng, W., He, M., Gu, L.-M., Lao, G., Wang, D., Mai, J.-X., Wu, H., Nie, S., & Huang, X. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.027 · Cited by 6
Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders
Blier, P., & Blier, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_3 · Cited by 7
Pharmacology of Intravenous Anesthetics
García, P. S., Whalin, M. K., & Sebel, P. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-48110-6.00010-7 · Cited by 6
Guo, L., Li, J., White, H., Xu, Z., Ren, J., Huang, X., Chen, Y., & Yang, K. (2023) · Campbell Systematic Reviews · doi:10.1002/cl2.1308 · Cited by 5
Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
Fancy, F., Rodrigues, N. B., Vincenzo, J. D. D., Chau, E., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., McKenzie, A., Phan, L., et al. (2023) · Focus · doi:10.1176/appi.focus.23021022 · Cited by 26
The next psychoactive drugs: From imipramine to ketamine
Carrillo, P., Petit, A., Gaillard, R., & Vinckier, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.09.039 · Cited by 5
Physiological markers of rapid antidepressant effects of allopregnanolone
Lambert, P. M., Lu, X., Zorumski, C. F., & Mennerick, S. J. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13023 · Cited by 5
Predictors of Clinical Recovery in Bipolar Disorders
Fico, G., Anmella, G., Murru, A., & Vieta, E. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_10 · Cited by 5
Interrelation of auto-immune process, endocrine disorders and depression
Mayorova, M. A., Петрова, Н. Н., Stroev, U. I., Churilov, L. P., & Shoenfeld, Y. (2020) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2020-1-8-19 · Cited by 5
Ketamin und andere N-Methyl-D-Aspartat-Rezeptor-Modulatoren zur Behandlung der Depression
Vestring, S., Domschke, K., & Normann, C. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01221-x · Cited by 5
What ketamine can teach us about the opioid system in depression?
Pérez-Caballero, L., Pérez, V., & Berrocoso, E. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1781812 · Cited by 5
Courtes, A. C., Jones, G. H., Henter, I. D., Shahani, L., Fries, G. R., Juruena, M. F., Soares, J. C., Zarate, C. A., & Machado‐Vieira, R. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120016 · Cited by 4
Self-citationPleiotropic modulation of the gut-brain-lung axis by ketamine and its enantiomers
Zhao, X., Zhang, X., Yuan, S., Hashimoto, K., & Zhang, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03590-8 · Cited by 4
Zheng, W., Gu, L.-M., Yang, X.-H., Zhou, Y., Wang, C., Lan, X., Zhang, B., & Ning, Y. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2138444 · Cited by 4
Yu, K., Song, Z., Zhang, B., Pan, Q., Gan, S., Yang, S., Yang, Q.-Y., Zuo, X., & Yin, Y. (2023) · Trials · doi:10.1186/s13063-023-07575-8 · Cited by 4
Geller, J. A., Keith, K., Smith, C., Pacilio, R. M., Arfken, C. L., Oxley, M., & Mischel, N. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100688 · Cited by 4
Falkenberg, I., Bitsch, F., Liu, W., Matsingos, A., Noor, L., Vogelbacher, C., Yildiz, C., & Kircher, T. T. J. (2023) · Trials · doi:10.1186/s13063-023-07556-x · Cited by 4
Anti-suicidal effects of IV ketamine in a real-world setting
O’Brien, B., Lee, J., Kim, S., Nandra, G. S., Pannu, P., Tamman, A. J. F., Amarneh, D. Y., Swann, A. C., Murphy, N., Averill, L. A., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115604 · Cited by 4
Antidepressant Actions of Ketamine and Its Two Enantiomers
Chang, L., Wei, Y., & Hashimoto, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_7 · Cited by 4
Kheirkhah, M., Mcdonald, N., Aepfelbacher, J., Rengasamy, M. L., Shivanekar, S. P., Spotts, C., Cooper, I., Baumeister, A., Bell, E., Do-Nguyen, K., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1642025 · Cited by 4
Self-citationKetamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Lie, P. E., Lie, T., Nguyen, M., & Lie, D. Y. C. (2026) · Healthcare · doi:10.3390/healthcare14050634 · Cited by 3
Srivastava, J., Yadav, J., & Dubey, N. (2026) · Cognitive Neurodynamics · doi:10.1007/s11571-026-10446-y · Cited by 3
Phillips, J. L., Blier, P., & Talbot, J. D. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100613 · Cited by 3
Next generation antidepressants with novel mechanisms for treatment resistant depression
Chen, M., Tu, P., & Su, T. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.005 · Cited by 3
Selinger, M. C., Compton, D. M., Morris, H., & Canty, T. J. (2023) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2023.1312016 · Cited by 3
de la Salle, S., Phillips, J. L., Blier, P., & Knott, V. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251319456 · Cited by 3
Lan, X., Liu, H., Wang, C., Li, W., Zhang, F., Hu, Z., Chen, X., You, Z., Ning, Y., & Zhou, Y. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00587-2 · Cited by 3
NMDA receptor antagonists as potential therapy in cerebellar degenerative disorders
Belozor, О. S., Shuvaev, А. N., Fritsler, Y. V., & Shuvaev, А. N. (2022) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2022.2.7 · Cited by 3
Ketamine Infusion (KI) in Treatment Resistant Depression (TRD): Retrospective Clinical Data Analysis
Griffiths, C., O’Neill-Kerr, A., Vai, R. D., Sore, T., & da Silva, K. M. (2019) · Open Journal of Depression · doi:10.4236/ojd.2019.83007 · Cited by 3
Psychotropes du futur : de l’imipramine à la kétamine
Carrillo, P., Petit, A., Gaillard, R., & Vinckier, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.09.038 · Cited by 3
Martin, J., Nezhad, F. G., Rueda, A., Lee, G. H., Charlton, C. E., Soltanzadeh, M., Ladha, K. S., Krishnan, S., Diaconescu, A. O., & Bhat, V. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308413 · Cited by 2
Myerson, J., Rufino, K. A., Mathew, S. J., Fletcher, M., Puri, N., & Oh, H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119727 · Cited by 2
Choi, K., Lee, T., Lee, S., & Im, C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf042 · Cited by 2
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Halma, M. T. J., Levy, R., & Varón, J. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100286 · Cited by 2
Chronic Pain and Major Depression: Shared Psychological and Neurobiological Mechanism
Lee, S.-H., & Kim, Y. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_9 · Cited by 3
Gee, S., Wratten, C., Cairns, R., Santhouse, A. M., & Taylor, D. M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-239587 · Cited by 2
Depression roundtable: Is there a role for BoNT?
Kels, L. H. (2023) · Toxicon · doi:10.1016/j.toxicon.2023.107148 · Cited by 2
An exploration of actigraphy in the context of ketamine and treatment‐resistant depression
Punturieri, C., Duncan, W. C., Greenstein, D. K., Shandler, G., Zarate, C. A., & Evans, J. W. (2023) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1984 · Cited by 2
Self-citationHu, X., Liu, J., Wu, J., Xiong, Z., & Li, N. (2025) · Journal of Analysis and Testing · doi:10.1007/s41664-025-00369-8 · Cited by 2
Affektive Störungen am Beispiel der unipolaren Depression
Köhler, S., & Walter, H. (2020) · Springer eBooks · doi:10.1007/978-3-662-59038-6_12 · Cited by 3
Ketamine and depression: An old drug in search of a clinical indication
White, P. F. (2021) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2021.110500 · Cited by 2
Lepow, L., Luckenbaugh, D. A., Park, L., Henter, I. D., & Zarate, C. A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.10.023 · Cited by 2
Self-citation
Metadata
- Authors
- Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U.
- Affiliations
- Northwell Health (US)
- University Hospital Carl Gustav Carus (DE)
- Corresponding author
- Correll, C. U.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2016-02-12
- Volume
- 46
- Issue
- 7
- Pages
- 1459-1472
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC5116384
- OpenAlex
- W2326374493
- Cited by
- 359
- References
- 56
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 26 · 2023: 44 · 2022: 40 · 2021: 56 · 2020: 42 · 2019: 33 · 2018: 39 · 2017: 24 · 2016: 12
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Stanley Medical Research Institute
- Sunovion
- National Alliance for Research on Schizophrenia and Depression
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Astellas Pharma
- Shionogi
- Servier
- H. Lundbeck A/S
- National Institutes of Health
- Genentech
- National Institute of Mental Health (P30MH090590, ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, bipolar depression, treatment-resistant depression, antidepressant efficacy, remission, discontinuation, adverse effects, class effect, placebo response, treatment cost-effectiveness
- MeSH terms
- Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Outcome Assessment, Health Care, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
